Dynamic antigen expression and cytotoxic T cell resistance in HIV reservoir clones

Read full text
Authors: Isabella A. T. M. Ferreira, Alberto Herrera, Tan Thinh Huynh, E. N. Stone, Noemi Linden, Cristian Ovies, Yanqin Ren, Cíntia Bittar, Virender Kumar Pal, Ethan Naing, Parul Sinha, A. Danesh
+25 more Eva Kaltenthaler Matt Stevenson, Shane Vedova, Fitty L Liu, Louise Leyre, Skylar Shea, E. Frances Wells, Itzayana G. Miller, Marie Canis, Ana Rafaela Teixeira, Susan Moir, Tae-Wook Chun, Colin Kovacs, Madeleine S. Gastonguay, Alison L. Hill, Shy Genel, P. Zumbo, Doron Betel, Elias K. Halvas, Guinevere Q. Lee, Rachel Scheck, Marina F. Caskey, Paul D. Bieniasz, Nathan L. Board, Michel C. Nussenzweig, R. Brad Jones
Cited by: 3
References: 60

Abstract

Clonally expanded CD4 + T-cells harboring rebound-competent HIV persist lifelong during ART 1-5 . Latency is considered the principal barrier to viral eradication and has resisted pharmacological reversal 6,7 , yet sustained immune pressure appears to erode reservoirs 8-15 . Recent advances have yielded glimpses into exceptionally rare reservoir-harboring cells, implicating pro-survival properties in persistence 16-18 . Here, we isolate and characterize authentic reservoir clones (ARCs) that robustly proliferate and accumulate while producing infectious virus, without overtly succumbing to cytopathicity. At any moment, only small fractions of ARCs expressed HIV proteins, a state associated with conserved host transcriptional programs but remarkably refractory to potent T-cell stimulation. Nevertheless, sustained co-culture with a CD8 + cytotoxic T-lymphocyte clone substantially culled proliferating ARCs, revealing time-integrated vulnerability to immune pressure. The corresponding ex vivo CD8 + T-cell response was poorly cytotoxic and in vivo erosion of ARCs occurred only slowly. A regulatory T-cell ARC displayed pronounced cell-intrinsic resistance to CTL—a longstanding hypothesis now directly demonstrated—linked to low oxidative stress and reversed with deferoxamine 19 , a hypoxic stress inducer and FDA-approved therapeutic. Overall, we provide novel insights into the vulnerabilities of reservoir clones to potent, sustained CTL pressure and highlight intrinsic resistance pathways as actionable therapeutic targets, opening opportunities for advancing immune-based HIV cure strategies.

Fields of Study & Subjects

HIV Research and Treatment Immune Cell Function and Interaction T-cell and B-cell Immunology

Publication details

Journal / source
Nature
Publisher
Springer Science and Business Media LLC
Volume
653
Issue
8115
Pages
850–860
Publication date
24 February 2026
Language
EN